NCT03381105Active, not recruiting
From PSA to Stockholm3: Study Part 1
From PSA to Stockholm3, a Naturalistic Effectiveness Multipart Research Program: Study Part 1
Source: ClinicalTrials.gov · Last updated 24 Apr 2023
Brief summary (registry, in English)
This part of the project aims to analyze the effectiveness of the Stockholm3 test in regular clinical practice, both in general practice and in the specialist health care, as a tool for detecting patients who need further diagnostics for prostate cancer.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 13431 (actual)
- First submitted
- 18 Dec 2017
- Start date
- 1 Sept 2017
- Primary completion date
- 31 Dec 2021
- Lead sponsor
- Helse Stavanger HF
- Diseases
- Prostate cancer
- NCT number
- NCT03381105
What you commit to
- Study type: Observational
- Participants enrolled: 13431
- From 1 Sept 2017 to the primary completion date, 31 Dec 2021
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- known prostate cancer
Who the study is looking for
- All men where a physicians in regular clinical work finds that there is an indication to take the test
Age in the registry: 18 years to - · Sex: Male · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Stavanger University Hospital Coordinator of this site? Confirm its status | Stavanger | Norway | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.